Oncotarget

Reviews:

Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker

Ru Wang, Xiao Li, Huimin Zhang, Ke Wang and Jianjun He _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75742-75755. https://doi.org/10.18632/oncotarget.20608

Metrics: PDF 1444 views  |   HTML 3167 views  |   ?  


Abstract

Ru Wang1, Xiao Li1, Huimin Zhang1, Ke Wang1 and Jianjun He1

1Department of Breast Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China

Correspondence to:

Jianjun He, email: chinahjj@163.com

Keywords: biomarker, liquid biopsy, ctDNA, breast cancer

Received: May 09, 2017     Accepted: August 17, 2017     Published: September 01, 2017

ABSTRACT

Circulating tumor DNA (ctDNA) in the blood of cancer patients contains much information on genetic and epigenetic profiles associated with cancer development, progression, and response to therapy. Analysis of ctDNA provides an opportunity for non-invasive sampling of tumor DNA repetitiously and therefore advance precision medicine. Recent development in massively parallel sequencing and digital genomic techniques support the analytical and clinical validity of ctDNA as a promising ‘liquid biopsy’ in human cancer. In this review, we discussed the current status of cell-free ctDNA including ctDNA biology, recently developed techniques for ctDNA detection, breast cancer specific detecting strategies, with a focus on clinical applications of ctDNA-based biomarkers in breast oncology.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20608